TRCT
FDMT icon

Tower Research Capital (TRC)’s 4D Molecular Therapeutics FDMT Stock Holding History

Tower Research Capital (TRC)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.3K Buy
6,110
+92
+2% +$896 ﹤0.01% 2350
2026
Q1 		$56K Buy
6,018
+3,799
+171% +$33.1K ﹤0.01% 2644
2025
Q4 		$16.6K Buy
2,219
+71
+3% +$720 ﹤0.01% 3240
2025
Q3 		$18.7K Sell
2,148
-5,506
-72% -$32.9K ﹤0.01% 3373
2025
Q2 		$28.4K Buy
7,654
+2,876
+60% +$10.1K ﹤0.01% 3454
2025
Q1 		$15.4K Sell
4,778
-45,475
-90% -$214K ﹤0.01% 3221
2024
Q4 		$280K Buy
50,253
+37,102
+282% +$291K 0.01% 1466
2024
Q3 		$142K Buy
13,151
+3,583
+37% +$59.5K ﹤0.01% 1945
2024
Q2 		$201K Buy
9,568
+8,586
+874% +$215K ﹤0.01% 2074
2024
Q1 		$31.3K Sell
982
-8,643
-90% -$221K ﹤0.01% 2615
2023
Q4 		$195K Buy
9,625
+8,506
+760% +$112K ﹤0.01% 2115
2023
Q3 		$14.2K Sell
1,119
-1,913
-63% -$32K ﹤0.01% 3701
2023
Q2 		$54.8K Sell
3,032
-5,334
-64% -$98.2K ﹤0.01% 2513
2023
Q1 		$144K Buy
8,366
+4,638
+124% +$90.2K ﹤0.01% 1559
2022
Q4 		$83K Sell
3,728
-673
-15% -$10.4K ﹤0.01% 1980
2022
Q3 		$35K Sell
4,401
-2,502
-36% -$22.7K ﹤0.01% 3468
2022
Q2 		$48K Buy
6,903
+5,121
+287% +$49.8K ﹤0.01% 2922
2022
Q1 		$27K Sell
1,782
-1,927
-52% -$30.3K ﹤0.01% 3248
2021
Q4 		$81K Buy
3,709
+610
+20% +$15K ﹤0.01% 2372
2021
Q3 		$84K Buy
3,099
+2,129
+219% +$60.7K ﹤0.01% 2534
2021
Q2 		$23K Buy
970
+366
+61% +$11.2K ﹤0.01% 3753
2021
Q1 		$26K Buy
+604
New +$26.8K ﹤0.01% 3677

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Tower Research Capital (TRC)'s FDMT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its 4D Molecular Therapeutics (FDMT) stake by 1.5% in Q2 2026, buying an estimated $896 and bringing the position to 6,110 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2350.

Tower Research Capital (TRC) first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $280K in Q4 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Tower Research Capital (TRC) held 6,110 shares of 4D Molecular Therapeutics worth $81.3K as of Q2 2026.
  • Tower Research Capital (TRC) bought 92 4D Molecular Therapeutics shares in Q2 2026, an estimated $896.
  • 4D Molecular Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2350 holding.
  • Tower Research Capital (TRC) first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s 4D Molecular Therapeutics position peaked at $280K in Q4 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.